Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Currently on Methotrexate Therapy
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2005-03-28
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 499
- Registration Number
- NCT00106522
A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2005-03-28
- Last Posted Date
- 2010-06-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 623
- Registration Number
- NCT00106548
A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2005-03-28
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1220
- Registration Number
- NCT00106574
A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2005-03-28
- Last Posted Date
- 2014-02-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1196
- Registration Number
- NCT00106535
GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection
Phase 3
Completed
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2005-03-07
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 337
- Registration Number
- NCT00105079
A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.
Phase 2
Withdrawn
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2005-02-24
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00104143
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
Phase 4
Terminated
- Conditions
- HIV Infection
- First Posted Date
- 2005-01-10
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 8
- Registration Number
- NCT00100984
A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain
Phase 3
Terminated
- Conditions
- Bone NeoplasmNeoplasm MetastasisPain
- Interventions
- First Posted Date
- 2004-12-10
- Last Posted Date
- 2017-08-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 96
- Registration Number
- NCT00099177
A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease
Phase 3
Terminated
- Conditions
- PainNeoplasm MetastasisBone Neoplasm
- Interventions
- First Posted Date
- 2004-12-10
- Last Posted Date
- 2017-08-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 163
- Registration Number
- NCT00099203
A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients
- First Posted Date
- 2004-09-06
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 63
- Registration Number
- NCT00090766
© Copyright 2025. All Rights Reserved by MedPath